GHK-Cu

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. The free tripeptide and its copper complex are distinct materials with different appearance, solubility behaviour and analytical signatures; the complex is characteristically blue and its copper stoichiometry is part of its identity. Identity is confirmed by mass spectrometry and, where the specification requires it, by copper content determination; purity of the peptide component is measured by reversed-phase HPLC. All analytical values on this record come from the supplier specification sheet and batch certificate of analysis.

The tripeptide was identified in human plasma in the 1970s during work on factors that altered the behaviour of cultured hepatic tissue, and its high affinity for copper(II) was characterised shortly afterwards. It has since been studied for decades as a copper-transport motif, and copper-peptide chemistry is one of the better-characterised areas in this catalogue. A large secondary literature exists in cosmetic science, which is a different evidentiary standard from clinical pharmacology and should not be read as one.

A second reason the record is unusually long-running is analytical: the complex is coloured, water-soluble and easy to characterise, so it was tractable to study with the instrumentation available when it was first described. That accessibility produced a broad but shallow literature, with many small studies across many endpoints and comparatively few designed to test a specific hypothesis rigorously.

Published work examines copper coordination chemistry, effects on collagen and glycosaminoglycan synthesis in fibroblast culture, modulation of metalloproteinase and antiprotease expression in cultured skin models, and gene-expression profiling studies reporting broad transcriptional changes in fibroblasts exposed to the complex. Other reports examine antioxidant behaviour attributable to copper redox cycling. The copper ion is not incidental to these observations; much of the activity described in the literature is copper-dependent, which complicates attribution to the peptide itself.

Copper binding affinity and coordination geometry are well established by independent physicochemical methods. Effects on collagen synthesis in fibroblast culture have been reported repeatedly across separate laboratories over several decades. Topical dermatological studies in humans exist and include controlled designs, which is more than most compounds in this catalogue can claim, though they address cosmetic endpoints rather than disease outcomes. Analytical identification of the complex is unambiguous.

Physicochemical work on the complex — stability constants, coordination geometry, redox behaviour under defined conditions — is the strongest part of this record and has been performed by groups with no interest in any biological claim. That independence matters: results generated by investigators without a stake in the outcome carry more weight than the same result produced inside a programme organised around a hypothesis.

There are no completed randomised controlled trials establishing systemic efficacy for any medical indication. The controlled human data are topical, small, and cosmetic in endpoint. Gene-expression findings come from a small number of related papers and have not been broadly replicated; transcriptomic breadth is easily overstated when derived from a single cell model. Copper-dependence is a confounder that few studies isolate: comparisons against equimolar copper salts are rare, so the specific contribution of the peptide carrier is often unresolved. Rodent wound-healing studies are small and frequently unblinded. Long-term data of any kind are absent.

There is a further analytical caveat that bears on how the literature should be read. Some published work uses the free tripeptide, some uses the pre-formed copper complex, and some adds copper salts to culture medium containing the peptide, producing a complex of uncertain stoichiometry. These are not interchangeable experimental conditions, and papers do not always state which was used. Where the copper source or the peptide-to-copper ratio is unreported, the result is difficult to interpret and impossible to reproduce precisely.

Store the lyophilised solid per the storage conditions on this record, protected from light and moisture. Copper complexes are sensitive to chelating buffers and to pH extremes, both of which can dissociate the complex and change what is actually present in a preparation. Colour change in solution is a practical indicator that the copper coordination state has altered. This section describes laboratory handling of the material as supplied and contains no preparation or administration procedure.

Copper content, where the specification includes it, is determined by elemental analysis rather than inferred from the peptide assay, and a certificate that reports only chromatographic purity has characterised the peptide component alone. For a material whose defining feature is a coordinated metal ion, that is a partial picture, and it is reasonable to ask a supplier for the elemental result.

Citations are listed below with verified PMIDs linking to the primary records. See testing methodology for how purity and identity values are established, sourcing standards for documentation requirements, and the compound index for related records.